Evidence map›Paper›PMID 12454053›Full record

ArticleGenetics2002

A novel class of secA alleles that exert a signal-sequence-dependent effect on protein export in Escherichia coli.

Karim Khatib, Dominique Belin

Abstract read
In one paragraph

Article in Genetics, 2002. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Karim KhatibDepartment of Pathology, University of Geneva, Switzerland.
Dominique Belin

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The murine plasminogen activator inhibitor 2 (PAI2) signal sequence inefficiently promotes the export of E. coli alkaline phosphatase (AP). High-level expression of PAI2::AP chimeric proteins from the arabinose P(BAD) promoter is toxic and confers an Ara(S) phenotype. Most Ara(R) suppressors map to secA, as determined by sequencing 21 independent alleles. Mutations occur throughout the gene, including both nucleotide binding domains (NBDI and NBDII) and the putative signal sequence binding domain (SSBD). Using malE and phoA signal sequence mutants, we showed that the vast majority of these secA suppressors exhibit weak Sec phenotypes. Eight of these secA mutations were further characterized in detail. Phenotypically, these eight suppressors can be divided into three groups, each localized to one domain of SecA. Most mutations allow near-normal levels of wild-type preprotein export, but they enhance the secretion defect conferred by signal sequence mutations. Interestingly, one group exerts a selective effect on the export of PAI2::AP when compared to that of AP. In conclusion, this novel class of secA mutations, selected as suppressors of a toxic signal sequence, differs from the classical secA (prlD) mutations, selected as suppressors of defective signal sequences, although both types of mutations affect signal sequence recognition.

Indexed as

Bacterial ProteinsAdenosine TriphosphatasesAlkaline PhosphataseAnimalsDNA Mutational AnalysisEscherichia coliEscherichia coli ProteinsMembrane Transport ProteinsMiceMutationPeriplasmic Binding ProteinsPlasminogen Activator Inhibitor 2Protein Sorting SignalsProtein TransportRecombinant Fusion ProteinsSecA ProteinsAdenosine TriphosphatasesAlkaline PhosphataseBacterial ProteinsEscherichia coli ProteinsMalE protein, E coliMembrane Transport ProteinsPeriplasmic Binding ProteinsPlasminogen Activator Inhibitor 2Protein Sorting SignalsRecombinant Fusion ProteinsSecA ProteinsSEC Translocation Channels

Identifiers

PMID12454053
PMCPMC1462312

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.